Major Depression With Psychotic Features
9
0
1
5
Key Insights
Highlights
Success Rate
63% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 67/100
33.3%
3 terminated out of 9 trials
62.5%
-24.0% vs benchmark
33%
3 trials in Phase 3/4
20%
1 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (9)
Academic-Community EPINET (AC-EPINET)
EPI-MINN: Targeting Cognition and Motivation - National
Multi-modal Assessment of Gamma-aminobutyric Acid (GABA) Function in Psychosis
Mediators and Moderators of Treatment Outcome in Recent-Onset Psychosis
Multifamily Psychoeducation and Cognitive Remediation for Recent-Onset Psychosis
Social Cognition in Longstanding Psychosis
Reducing Internalized Stigma in People With Serious Mental Illness
Treatment of Depression With Quetiapine
Treatment of Major Depressive Disorder With Psychotic Features.